certara is a leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes. certara’s solutions, which span the drug development and patient care lifecycle, help increase the probability of regulatory and commercial success by using the most scientifically advanced modeling and simulation technologies and regulatory strategies. its clients include hundreds of global biopharmaceutical companies, leading academic institutions and key regulatory agencies. for more information, visit www.certara.com.
Company profile
Ticker
CERT
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Microsoft • Oracle • Mobileye Global Inc - Ordinary Shares • Activision Blizzard • Gen Digital • Vmware • Adobe • Salesforce • BlackBerry • Dayforce ...
SEC CIK
Corporate docs
Subsidiaries
Analytica LA-SER International, Inc. • BaseCase, Inc. • BioMedCom Consultants, Inc. Canada • Certara Australia Pty Ltd Australia • Certara Canada Corporation Canada • Certara France S.a.r.l. • Certara Germany GmbH • Certara G.K. • Certara Holdco, Inc. • Certara Holding, Inc. ...
CERT stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Certara Reports First Quarter 2024 Financial Results
7 May 24
DEFA14A
Additional proxy soliciting materials
12 Apr 24
ARS
2023 FY
Annual report to shareholders
10 Apr 24
DEFA14A
Additional proxy soliciting materials
10 Apr 24
DEF 14A
Definitive proxy
10 Apr 24
PRE 14A
Preliminary proxy
29 Mar 24
D
Indefinite amount in equity
27 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Certara Reports Fourth Quarter 2023 Financial Results
29 Feb 24
Transcripts
CERT
Earnings call transcript
2024 Q1
7 May 24
CERT
Earnings call transcript
2023 Q4
29 Feb 24
CERT
Earnings call transcript
2023 Q3
8 Nov 23
CERT
Earnings call transcript
2023 Q2
9 Aug 23
CERT
Earnings call transcript
2023 Q2
9 Aug 23
CERT
Earnings call transcript
2023 Q1
8 May 23
CERT
Earnings call transcript
2022 Q4
1 Mar 23
CERT
Earnings call transcript
2022 Q3
8 Nov 22
CERT
Earnings call transcript
2022 Q2
9 Aug 22
CERT
Earnings call transcript
2022 Q1
8 May 22
Latest ownership filings
4/A
William F Feehery
5 Apr 24
4
PATRICK F SMITH
4 Apr 24
4
Richard M. Traynor
3 Apr 24
4
PATRICK F SMITH
3 Apr 24
4
NICOLETTE D SHERMAN
3 Apr 24
4
Leif E Pedersen
3 Apr 24
4
John E Gallagher
3 Apr 24
4
Robert Aspbury
3 Apr 24
4
William F Feehery
3 Apr 24
144
Notice of proposed sale of securities
2 Apr 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 272.31 mm | 272.31 mm | 272.31 mm | 272.31 mm | 272.31 mm | 272.31 mm |
Cash burn (monthly) | (no burn) | (no burn) | 17.87 mm | 1.81 mm | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 131.66 mm | 13.36 mm | n/a | n/a |
Cash remaining | n/a | n/a | 140.66 mm | 258.96 mm | n/a | n/a |
Runway (months of cash) | n/a | n/a | 7.9 | 142.9 | n/a | n/a |
Institutional ownership, Q4 2023
69.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 157 |
Opened positions | 22 |
Closed positions | 65 |
Increased positions | 51 |
Reduced positions | 61 |
13F shares | Current |
---|---|
Total value | 1.29 tn |
Total shares | 110.94 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Arsenal Capital Partners Iii | 29.95 mm | $534.39 mm |
Vanguard | 12.54 mm | $220.66 bn |
Mubadala Investment Co PJSC | 9.62 mm | $169.13 bn |
Baillie Gifford & Co | 8.92 mm | $156.93 bn |
William Blair Investment Management | 7.04 mm | $123.87 bn |
Arsenal Capital | 6.39 mm | $231.24 mm |
Clearbridge Advisors | 4.14 mm | $72.83 bn |
JPM JPMorgan Chase & Co. | 4.01 mm | $70.51 bn |
STT State Street | 3.49 mm | $61.36 bn |
Riverbridge Partners | 2.82 mm | $49.54 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Apr 24 | Patrick F Smith | Common Stock | Sell | Dispose S | No | Yes | 17.77 | 422 | 7.50 k | 50,091 |
2 Apr 24 | Patrick F Smith | Common Stock | Sell | Dispose S | No | Yes | 16.77 | 4,740 | 79.49 k | 50,513 |
2 Apr 24 | Patrick F Smith | Common Stock | Sell | Dispose S | No | Yes | 17.67 | 328 | 5.80 k | 55,253 |
2 Apr 24 | Patrick F Smith | Common Stock | Sell | Dispose S | No | Yes | 16.75 | 3,024 | 50.65 k | 55,581 |
2 Apr 24 | Patrick F Smith | Common Stock | Sell | Dispose S | No | Yes | 17.72 | 649 | 11.50 k | 58,605 |
2 Apr 24 | Patrick F Smith | Common Stock | Sell | Dispose S | No | Yes | 16.76 | 5,264 | 88.22 k | 59,254 |
1 Apr 24 | Feehery William F | Common Stock | Payment of exercise | Dispose F | No | No | 17.88 | 14,115 | 252.38 k | 2,249,154 |
1 Apr 24 | Feehery William F | Common Stock | Option exercise | Acquire M | No | No | 0 | 33,219 | 0.00 | 2,263,269 |
1 Apr 24 | Feehery William F | Common Stock | Payment of exercise | Dispose F | No | No | 17.88 | 15,543 | 277.91 k | 2,230,050 |
1 Apr 24 | Feehery William F | Common Stock | Option exercise | Acquire M | No | No | 0 | 36,580 | 0.00 | 2,245,593 |
News
Certara Q1 2024 GAAP EPS $0.10, Inline, Sales $96.654M Beat $93.637M Estimate
7 May 24
Keybanc Upgrades Certara to Overweight, Announces $23 Price Target
10 Apr 24
Decoding 4 Analyst Evaluations For Certara
4 Apr 24
JMP Securities Initiates Coverage On Certara with Market Perform Rating
4 Apr 24
UBS Maintains Neutral on Certara, Raises Price Target to $20
1 Mar 24
Press releases
Treatment AI (CSE: TRUE) Unveils New AI-Powered Solutions Revolutionizing Medical Education
18 Apr 24
Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform
16 Apr 24
Unleashing AI in Healthcare: The Game-Changing Partnership Between Treatment AI (CSE: TRUE) and aiXplain concurrent with Federal Momentum
16 Apr 24
AI Transforms Healthcare Stocks in 2024: Revolutionizing Medicine Across the Globe
11 Apr 24
Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference
9 Apr 24